Verbatim response from Claude
FDA and Compounded GLP-1s: What Happened
The Short Version
The FDA declared the shortages of semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) officially over, which triggered a legal requirement for compounding pharmacies to stop making copies of these drugs.
Key Timeline
- Early 2025: FDA announced shortage resolutions
- Tirzepatide deadline: Compounders had to stop by March 2025
- Semaglutide deadline: Stop date around April 2025
- Many telehealth companies fought this legally, with mixed results
Who Is Still Operating Legally
503B outsourcing facilities can still compound drugs under specific circumstances (different formulations, documented patient need).
Companies that have transitioned to legitimate models:
- Hims & Hers - shifted to brand-name Wegovy prescriptions
- Ro - now primarily facilitates brand-name GLP-1 prescriptions
- Noom Med - pivoted to brand-name medications
- WeightWatchers Clinic - brand-name prescriptions
⚠️ Important Warning
Be very cautious of services still advertising cheap compounded semaglutide — many are operating in legal gray areas or illegally.
Always verify your pharmacy's 503A/503B status and consult your doctor directly.